FAIRFIELD, N.J., June 15, 2012 /PRNewswire/ -- Aperture Health, Inc. (OTC APRE) is intending to capitalize on the strength of management's experience in the coordination of care at home and  the direct provision of hi-tech disease specific pharmacy services in the alternate care setting.  Management believes that Jim Hennig's 30 years of experience in the pharmacy industry, including 10 years building, directing and managing physician partnered pharmacy enterprises will provide confidence to the market in Aperture's ability to penetrate and provide exceptional service offerings into the growing long term disease management arena.

James Hennig, R.Ph., Chief Executive Officer and Chairman of the Board of Directors commented, "With the increasing focus being placed on alternate site therapeutics, in particular the home, we are highly confident in our ability to expand our IV therapy service capabilities by combining hi-tech nursing, clinical pharmacy, and medication management services coupled with streamlined communication to all medical providers involved in the patient's care. We can play an integral part in the hyper growth of disease specific medical management in today's healthcare environment."

About Aperture Health, and Triad Therapeutics

Aperture Health through its wholly owned subsidiary Triad Therapeutics operates a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad

Safe Harbor

Certain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business.  Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. The Company's actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad's selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions.  Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company's OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com .  All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.  The information set forth herein speaks only as of the date hereof.

SOURCE Aperture Health, Inc.

Copyright 2012 PR Newswire

Elinx (CE) (USOTC:ELNX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Elinx (CE)
Elinx (CE) (USOTC:ELNX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Elinx (CE)